Jan Kosťun1, Martin Pešta2,3,4, Jiří Sláma5, Robert Slunéčko6, Pavel Vlasák1, Jiří Bouda1, Zdeněk Novotný1, Ondřej Topolčan4, Radek Kučera4, Vlastimil Kulda7, Kateřina Houfková2, Denis Berezovskiy1, Alena Bartáková1, Jiří Presl1. 1. Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Prague, Czech Republic. 2. Department of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. 3. Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. 4. Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. 5. Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University, General University Hospital, Prague, Czech Republic. 6. Sikl's Department of Pathology, University Hospital Pilsen, Charles University, Prague, Czech Republic. 7. Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic.
Abstract
BACKGROUND AND OBJECTIVES: Utilisation of the one-step nucleic acid amplification (OSNA) molecular biology method for the detection of the metastatic involvement of sentinel lymph nodes (SLNs) in endometrial cancer (EC) patients. A comparison with histopathological ultrastaging and a description of the clinical consequences. METHODS: Surgically treated EC patients underwent detection of SLNs. Nodes greater than 5 mm were cut into sections 2-mm thick parallel to the short axis of the node. Odd sections were examined according to the OSNA method, while even ones according to an appropriate ultrastaging protocol. Nodes less than or equal to 5 mm were cut into halves along the longitudinal axis with one half examined according to the OSNA method and the other half by ultrastaging. RESULTS: Fifty-eight patients were included and 135 SLNs were acquired. Both ultrastaging and OSNA agreed on 116 results. According to the OSNA method, 20.69% more patients were classified into International Federation of Gynecology and Obstetrics (FIGO) stage III. When comparing the results of the OSNA method to the conclusions of ultrastaging as a reference method, sensitivity of 90.9%, specificity of 85.5% and concordance of 85.9% were attained. CONCLUSIONS: The results of the OSNA method showed a higher frequency of detection of micrometastases and included 20.69% more patients into FIGO stage III.
BACKGROUND AND OBJECTIVES: Utilisation of the one-step nucleic acid amplification (OSNA) molecular biology method for the detection of the metastatic involvement of sentinel lymph nodes (SLNs) in endometrial cancer (EC) patients. A comparison with histopathological ultrastaging and a description of the clinical consequences. METHODS: Surgically treated EC patients underwent detection of SLNs. Nodes greater than 5 mm were cut into sections 2-mm thick parallel to the short axis of the node. Odd sections were examined according to the OSNA method, while even ones according to an appropriate ultrastaging protocol. Nodes less than or equal to 5 mm were cut into halves along the longitudinal axis with one half examined according to the OSNA method and the other half by ultrastaging. RESULTS: Fifty-eight patients were included and 135 SLNs were acquired. Both ultrastaging and OSNA agreed on 116 results. According to the OSNA method, 20.69% more patients were classified into International Federation of Gynecology and Obstetrics (FIGO) stage III. When comparing the results of the OSNA method to the conclusions of ultrastaging as a reference method, sensitivity of 90.9%, specificity of 85.5% and concordance of 85.9% were attained. CONCLUSIONS: The results of the OSNA method showed a higher frequency of detection of micrometastases and included 20.69% more patients into FIGO stage III.
Authors: Antonio Raffone; Antonio Travaglino; Angela Santoro; Italia Esposito; Giuseppe Angelico; Saveria Spadola; Gian Franco Zannoni Journal: Pathol Oncol Res Date: 2019-08-23 Impact factor: 3.201
Authors: A A Novelli; A Puppo; M Ceccaroni; E Olearo; G Monterossi; G Mantovani; S Pelligra; P L Olearo; F Fanfani; G Scambia Journal: Facts Views Vis Obgyn Date: 2020-10-08
Authors: Josef Vodicka; Martin Pesta; Vlastimil Kulda; Katerina Houfkova; Bohuslava Vankova; Jakub Sebek; Martin Skala; Jakub Fichtl; Kristyna Prochazkova; Ondrej Topolcan Journal: Cells Date: 2020-12-04 Impact factor: 6.600
Authors: Enrique Trilla; Juan Morote; Mercè Cuadras; Jacques Planas; Ana Celma; Lucas Regis; Inés M de Torres; M Eugenia Semidey Journal: BMC Cancer Date: 2022-04-02 Impact factor: 4.430
Authors: Francesco Crafa; Serafino Vanella; Onofrio A Catalano; Kelsey L Pomykala; Mario Baiamonte Journal: World J Gastroenterol Date: 2022-08-14 Impact factor: 5.374
Authors: Katarzyna Gęca; Karol Rawicz-Pruszyński; Jerzy Mielko; Radosław Mlak; Katarzyna Sędłak; Wojciech P Polkowski Journal: Cells Date: 2020-09-25 Impact factor: 6.600